GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2014

California Peptide Research Taken Over by Echelon

  • Echelon Biosciences (EBI) acquired California Peptide Research (CPRI) to broaden its line of biochemicals and research peptides. EBI’s primary customers are pharmaceutical and R&D companies.

    According to Transparency Market Research, "…the global peptide therapeutics market was valued at $14.1 billion in 2011 and is estimated to reach a market worth $25.4 billion in 2018."

    "Peptide therapeutics show neurological applications, including Alzheimer's disease," said W. Tim Miller, EBI’s CEO, "along with broader capabilities for developing assays [that are] superior to traditional methods. [The acquisition] will provide Echelon an expanded offering of research reagents to our pharmaceutical and diagnostic customers, and incorporate the peptide expertise into our own research and development."

    CPRI will relocate operations from Napa, CA, to the Salt Lake City-based facility of EBI, and join corporate divisions that include Logan, UT-based Frontier Scientific and Newark, DE-based Frontier Scientific Services.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »